Brosfarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 289,283 | 832,880 | 791,136 | 1,035,141 | 1,199,769 | 2,313,293 | 4,741,029 | 9,491,514 |
| Profit before tax | - | - | - | - | - | - | - | 432,481 |
| Net profit | 40,938 | 27,495 | 118 | 91,699 | 1,431 | 70,412 | 79,125 | 371,283 |
| Equity | 41,641 | 69,135 | 69,253 | 160,847 | 162,278 | 232,690 | 311,815 | 650,598 |
| Liabilities | 11,988 | 13,994 | 69,463 | 119,769 | 121,146 | 176,032 | 301,508 | 256,980 |
| Non-current assets | 0 | 1,873 | 4,834 | 30,537 | 5,332 | 56,462 | 44,295 | 12,166 |
| Current assets | 53,577 | 81,256 | 95,844 | 155,343 | 167,768 | 175,126 | 385,637 | 895,412 |
| Total assets | 53,577 | 83,129 | 100,678 | 185,880 | 173,100 | 231,588 | 429,932 | 907,578 |
|
Taxes paid
|
||||||||
| Social insurance contributions | - | - | - | - | - | 4,635 | 13,905 | 18,558 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +187.9% | -5.0% | +30.8% | +15.9% | +92.8% | +104.9% | +100.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 76.4% | 33.1% | 0.1% | 49.3% | 0.8% | 30.4% | 18.4% | 40.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 98.3% | 39.8% | 0.2% | 57.0% | 0.9% | 30.3% | 25.4% | 57.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 14.2% | 3.3% | 0.0% | 8.9% | 0.1% | 3.0% | 1.7% | 3.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | 4.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.2 | 1.0 | 0.7 | 0.7 | 0.8 | 1.0 | 0.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 93,823 | 277,627 | 263,712 | 345,047 | 334,822 | 677,055 | 1,137,838 | 2,372,879 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Brosfarma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-01-18 | 2022-01-20 | 0.02 |
| 2021-12-16 | 2022-01-12 | 0.02 |
| 2021-11-16 | 2021-12-05 | 0.02 |
Brosfarma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2024-12-12 | 2024-12-17 | 101.15 |
| 2024-12-08 | 2024-12-11 | 100.82 |
| 2024-12-05 | 2024-12-07 | 100.7 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Brosfarma, UAB, a Private Limited Liability Company with code 304596579, operates in wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €9.49M, up 100.2% year on year and 310.3% over two years. Net profit increased sharply to €371.3K from €79.1K in 2024 and €70.4K in 2023, lifting the profit margin to 3.9% after 1.7% in 2024 and 3.0% in 2023. The 2025 balance sheet strengthened further, with total assets of €907.6K, equity of €650.6K and liabilities of €257.0K. The equity ratio stood at 71.7% and debt-to-equity at 0.39, indicating a conservative capital structure. Asset turnover was high at 10.46x, reflecting strong sales generation relative to the asset base. Profitability ratios were also solid, with ROE at 57.1% and ROA at 40.9%. Revenue per employee reached €2.37M and profit per employee €92.8K, pointing to high productivity in 2025.